Gene therapy shot may ease diabetic nerve pain

NCT ID NCT01002235

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a gene therapy called Engensis (VM202) in 12 people with painful diabetic peripheral neuropathy. Participants received injections into their calf muscles to see if it was safe and could reduce pain. The study focused on safety and pain scores over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Engensis (VM202), a gene therapy given as injections into the calf muscle
What this could lead to
If it works, this could point toward a new way to ease nerve pain in people with diabetes.
What could go wrong
This is a very small, early-phase trial with only 12 people, so results may not apply widely. The main goal is safety, not proof of effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAINFUL DIABETIC PERIPHERAL NEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Diablo Clinical Research Hospital

    Walnut Creek, California, 94598, United States

  • Northwestern Memorial Hospital

    Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.